Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial-Reference-Cited by-同舟云学术

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

Published:2013-09 Issue:9896 Volume:382 Page:941-950
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Cefalu William T,Leiter Lawrence A,Yoon Kun-Ho,Arias Pablo,Niskanen Leo,Xie John,Balis Dainius A,Canovatchel William,Meininger Gary

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care;Cook;Diabet Med,2007

2. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012

3. Secondary failure of metformin monotherapy in clinical practice;Brown;Diabetes Care,2010

4. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus;Neumiller;Drugs,2010

5. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin;Devineni;Diabetes Obes Metab,2012

Cited by 614 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 inhibitor canagliflozin reduces visceral adipose tissue in db/db mice by modulating AMPK/KLF4 signaling and regulating mitochondrial dynamics to induce browning;Molecular and Cellular Endocrinology;2024-10

2. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

3. SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art;American Journal of Cardiovascular Drugs;2024-08-24

4. The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review;International Journal of Molecular Sciences;2024-06-27

5. Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors;International Journal of Molecular Sciences;2024-06-25